The Centers for Medicare & Medicaid Services (CMS) on April 23, 2019, released the Fiscal Year (FY) 2020 Medicare Hospital Inpatient Prospective Payment System (IPPS) Proposed Rule. The proposed rule will affect discharges occurring on or after Oct. 1, 2019. It is scheduled to be published in the Federal Register on May 3, 2019. Comments on the proposed rule are due by June 24, 2019.
Visit the CMS website for the IPPS fact sheet.
CMS projects that the rate increase, together with other proposed changes to IPPS payment policies, will increase IPPS operating payments by approximately 3.5 percent overall. When combined with proposed changes in uncompensated care payments, new technology add-on payments, low-volume hospital payments and capital payments, which are expected to increase payments by an additional 0.2 percent, CMS estimates a total increase in IPPS payments of approximately 3.7 percent.
CMS projects that total Medicare spending on inpatient hospital services, including the capital, will increase by about $4.7 billion in FY 2020. The proposed changes would apply to approximately 3,300 acute care hospitals and affect discharges occurring on or after Oct. 1, 2019
To increase payments to rural hospitals, CMS is proposing to increase the wage index for certain low-wage hospitals. As these changes are budget-neutral, this sets up a "winners vs. losers" scenario, with some hospitals in high-cost areas expected to see reduced payment rates. The increase would affect the hospitals in the bottom 25th percentile of the wage index. Under the new policy, those hospital's wage index would be increased by 50 percent of the difference between current policy and the wage index for the 25th percentile for all hospitals. Hospitals with a wage index in the 75th percentile or higher would see their wage index decreased to offset the higher spending. If finalized, the payment changes will be phased in over four years. CMS also proposes to place a 5 percent cap on the reduction of any hospital's wage index in a given year.
It is anticipated that there will be "winners and losers" across service lines as well. Service lines such as neurosurgery, other trauma, vascular services, neurology and orthopedics are expected to receive updates greater than 3 percent, while general surgery, cardiac services and medical oncology/hematology are proposed to see payment updates falling short of 3 percent.
Additionally, CMS is proposing to calculate the rural floor without hospitals that have been newly reclassified as "rural" (vs. "urban") to discourage state reclassification from taking advantage of Medicare payment policies.
In addition to proposing updates to methodologies for the calculation of Disproportionate Share Hospital (DSH) payments in 2019, CMS estimates that eligible DSHs will receive an overall increase of approximately $8.49 billion in 2020, which reflects an average increase of 2.61 percent. DSH payments in 2019 were approximately $8.27 billion. These changes are because of methodological changes in Factors 1 and 2, which are used to calculate payment rates.
CMS is also proposing to use a single year of data on uncompensated care costs from Worksheet S-10 for FY 2015 to determine Factor 3 for FY 2020. They are also seeking public comments on whether the CMS should, because of changes in the reporting instructions that became effective for FY 2017, alternatively use a single year of Worksheet S-10 data from the FY 2017 cost reports, instead of the FY 2015 Worksheet S-10 data, to calculate Factor 3 for FY 2020.
CMS proposes to modify the definition of "non-provider sites" to include critical access hospitals (CAHs). Hospitals may include residents training in a non-provider setting in its full-time equivalent (FTE) count if the hospital incurs the residents' salaries and fringe benefits while the residents are training at that site. CAHs are not considered non-provider sites under CMS' current policy. The proposed modification would allow hospitals to claim residents training in a CAH in its FTE count as long as the non-provider setting requirements are met.
CMS is proposing to adopt eight factors that CMS would use when deciding whether a measure should be removed from HRRP; update the definition of "dual eligible"; and, adopt a subregulatory process to address potential nonsubstantive changes to the payment adjustment factor components.
CMS is proposing that the VBP would use the same data as the Hospital-Acquired Conditions (HAC) Reduction Program to calculate the National Health Safety Network (NHSN) Healthcare-Associated Infection (HAI) measures beginning with Calendar Year (CY) 2020 data collection, which is when the Hospital Inpatient Quality Reporting (IQR) Program will cease collecting data on those measures. CMS is also proposing that the VBP would rely on the process used by the HAC Reduction Program to validate the NHSN HAI measures to ensure that the measure rates are accurate for use in the Hospital VBP Program.
CMS is proposing to specify the dates to collect data used to calculate hospital performance for the FY 2022 HAC Reduction Program; adopt eight factors that CMS would use when deciding whether a measure should be removed from the HAC Reduction Program; and, clarify administrative processes for validating NHSN HAI data submitted by hospitals to the Centers for Disease Control and Prevention (CDC).
CMS proposes to remove the Claims-Based Hospital-Wide All-Cause Unplanned Readmission measure and replace it with the proposed Hybrid Hospital-Wide All-Cause Readmission (Hybrid HWR) Measure with Claims and Electronic Health Record Data measure, and require reporting beginning with the FY 2026 payment determination after two years of voluntary reporting of the Hybrid HWR measure and establish reporting and submission requirements for the hybrid measures.
CMS also proposes to adopt two new opioid-related electronic clinical quality measures (eCQMs) beginning with the CY 2021 reporting period/FY 2023 payment determination: Safe Use of Opioids – Concurrent Prescribing eCQM; and, Hospital Harm – Opioid-Related Adverse Events eCQM. CMS is also proposing three changes for reporting eCQMs. These proposals align with the Promoting Interoperability Program's Clinical Quality Measure proposals. CMS also invites public comment on three potential new measures for the Hospital IQR Program: Hospital Harm—Severe Hypoglycemia eCQM, Hospital Harm—Pressure Injury eCQM and Cesarean Birth eCQM.
CMS proposes several policies related to these programs:
CMS also requests information on including more meaningful measures to combat the opioid epidemic, engaging vendors and providers in improving the efficiency of EHRs, and integrating data into the Hospital Compare website, among other topics.
CMS estimates that LTCH Prospective Payment System (PPS) payments would increase by approximately 0.9 percent, or $37 million, in FY 2020. LTCH PPS cases paid the standard federal payment rate (i.e., cases that meet clinical criteria) are expected to increase by 2.3 percent, or approximately $79 million, while cases continuing to transition to the site-neutral payment rate (i.e., cases that do not meet clinical criteria) are expected to decrease by approximately 4.9 percent, or roughly $41 million. The site-neutral estimate includes cases that will no longer be paid a blended rate as the statutory transitional period ends for LTCH discharges occurring in cost reporting periods beginning in FY 2020. CMS estimates that approximately 29 percent of LTCH PPS cases will be paid the site-neutral payment rate in FY 2020.
CMS is proposing to adopt two new quality measures related to transferring health information, including 1) Transfer of Health Information to the Provider-Post-Acute Care (PAC), and 2) Transfer of Health Information to the Patient-Post-Acute Care (PAC), to align with the Meaningful Measures Initiative and satisfy the quality measure domain of the Improving Medicare Post-Acute Care Transformation Act (IMPACT) Act. CMS also proposes to update the specifications to the LTCH QRP measure, Discharge to Community Post-Acute Care, by excluding nursing facility residents who already reside in the nursing home from the measure.
CMS is proposing to adopt one new measure and remove two existing measures, as well as publicly report performance data on the emergency department, infection and personnel vaccination measures. CMS is seeking public comment on potential future quality measures that could assess pain management without incentivizing the overprescribing of opioids, as well as those that could assess alternative pain management methodologies for individuals with cancer.
The proposed rule states that CMS has received a request to create a new Medicare Severity Diagnosis Related Group (MS-DRG) for procedures involving CAR T-cell therapies. The agency notes its belief that it may be premature to consider this since these therapies are new. For FY 2020, CAR T-cell therapies will continue to use the current MS-DRG assignment. However, CMS is seeking public comment on payment alternatives for CAR T-cell therapies and how these alternatives would affect access to care and incentives to lower drug prices.
CMS' NTAP allows for an additional payment for medical services or technologies found to be 1) new, 2) disproportionately costly to the existing MS-DRG, and 3) a substantial clinical improvement. This additional payment is equal to the lesser of:
CMS received feedback from stakeholders that the 50 percent add-on does not adequately reflect the cost of some extremely high-cost therapies (e.g., CAR T-cell therapy). Therefore, for FY 2020, CMS proposes to increase this percentage threshold to 65 percent in both of the above cases. CMS estimates that this increase in payments will total $110 million in FY 2020.
CMS notes that, over the years, there have been multiple requests for clarification as to what constitutes a substantial clinical improvement for NTAP and outpatient pass-through payments, and is seeking comments on the type of additional information and guidance that would be helpful. These comments will serve as the basis for future rulemaking.
CMS identified 17 new applications for NTAP for FY 2020:
CMS is proposing to maintain NTAP for 10 of the 13 technologies that currently receive these payments and discontinue NTAP for the remaining three technologies in FY 2020.
CMS proposes ending NTAP payment for the following:
CMS proposes to extend NTAP status for the following:
CMS proposed an alternative NTAP pathway for a medical device that receives U.S. Food and Drug Administration (FDA) marketing authorization and is part of an FDA expedited program for medical devices, which is currently the Breakthrough Devices Program.
If a medical device subject to one of the FDA's expedited programs has received marketing authorization from the FDA, CMS would consider that product "new" and "not substantially similar" to existing technology for purposes of the NTAP. Under this proposal, the medical device would only need to meet the cost criterion to receive the add-on payment. This change would begin with applications received for new technology add on payments for FY 2021.
Information contained in this alert is for the general education and knowledge of our readers. It is not designed to be, and should not be used as, the sole source of information when analyzing and resolving a legal problem. Moreover, the laws of each jurisdiction are different and are constantly changing. If you have specific questions regarding a particular fact situation, we urge you to consult competent legal counsel.
Please note that email communications to the firm through this website do not create an attorney-client relationship between you and the firm. Do not send any privileged or confidential information to the firm through this website. Click "accept" below to confirm that you have read and understand this notice.